Drugs make the FTSE stumble

clock

The benchmark FTSE 100 index has so far lost 10 points to 4,492 after UK stocks dropped, paced by drugmakers AstraZeneca and GlaxoSmithKline.

AstraZeneca fell 33p to 2,526p after a letter from US consumer watchdog Public Citizen said the drugmaker's Crestor cholesterol treatment is dangerous and should be removed from the market. GlaxoSmithKline also lost 12p to 1,158p after Citigroup cut its recommendation for the drugmaker’s shares to “hold” from “buy”. In Asia, Tokyo's Nikkei 225 index gained 36.25 points to 11,780.40 earlier today, and Hong Kong's Hang Seng rose 21.84 points to 12,185.52. On Wall Street, trading ended down Thursday as the Dow Jones Industrial Average index lost 35.76 points to 10,443.81 by the close....

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Partner Insight: Beyond 60/40

Partner Insight: Beyond 60/40

Invesco
clock 25 March 2024 • 5 min read
'Fundamental shift': Why transparent investing really matters

'Fundamental shift': Why transparent investing really matters

‘There needs to be a concerted shift towards greater openness’

Simon Camilleri
clock 18 March 2024 • 4 min read
Partner Insight: Passive and active — the case for both

Partner Insight: Passive and active — the case for both

Invesco
clock 18 March 2024 • 4 min read